title: ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.
abstract: Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of NSCLC patients present with advanced disease and have an average 5-year survival rate of 5%. Currently, the standard of care for NSCLC includes treatment with a platinum-based chemotherapy regimen. However, not all patients benefit equally from such treatment. Therefore, recent pharmacogenomic studies have been performed in order to identify specific biomarkers that may allow for patient-tailored treatment strategies. One such biomarker is expression of the excision repair cross-complementation group 1 protein, ERCC1.
authors.affiliation: Hayes, Inc.
authors.forename: Diane
authors.initials: D
authors.lastname: Allingham-Hawkins
authors.forename: Andrew
authors.initials: A
authors.lastname: Lea
authors.forename: Susan
authors.initials: S
authors.lastname: Levine